These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 36038616)

  • 21. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.
    Bardia A; Hurvitz SA; Rugo HS; Brufsky A; Cortes J; Loibl S; Piccart M; Cowden J; Spears P; Carey LA
    Future Oncol; 2021 Oct; 17(30):3911-3924. PubMed ID: 34467774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
    Bardia A; Messersmith WA; Kio EA; Berlin JD; Vahdat L; Masters GA; Moroose R; Santin AD; Kalinsky K; Picozzi V; O'Shaughnessy J; Gray JE; Komiya T; Lang JM; Chang JC; Starodub A; Goldenberg DM; Sharkey RM; Maliakal P; Hong Q; Wegener WA; Goswami T; Ocean AJ
    Ann Oncol; 2021 Jun; 32(6):746-756. PubMed ID: 33741442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors.
    Sathe AG; Singh I; Singh P; Diderichsen PM; Wang X; Chang P; Taqui A; Phan S; Girish S; Othman AA
    Clin Pharmacokinet; 2024 May; 63(5):669-681. PubMed ID: 38578394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.
    Kalinsky K; Spring L; Yam C; Bhave MA; Ntalla I; Lai C; Sjekloca N; Stwalley B; Stokes M; Taylor A; Nanda R
    Breast Cancer Res Treat; 2024 Jun; ():. PubMed ID: 38904892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
    Weiss J; Glode A; Messersmith WA; Diamond J
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany.
    Reinisch M; Bruzas S; Spoenlein J; Shenoy S; Traut A; Harrach H; Chiari O; Cremer E; Ataseven B; Gubelt L; Kuemmel S
    Ther Adv Med Oncol; 2023; 15():17588359231200454. PubMed ID: 37789989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer.
    Michaleas S; Moreno Oliver A; Mueller-Berghaus J; Sarac SB; van der Elst ME; Müller-Egert S; Zander H; Enzmann H; Pignatti F
    ESMO Open; 2022 Jun; 7(3):100497. PubMed ID: 35642987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
    Shastry M; Jacob S; Rugo HS; Hamilton E
    Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Diamond JR; Moroose RL; Isakoff SJ; Starodub AN; Shah NC; O'Shaughnessy J; Kalinsky K; Guarino M; Abramson V; Juric D; Tolaney SM; Berlin J; Messersmith WA; Ocean AJ; Wegener WA; Maliakal P; Sharkey RM; Govindan SV; Goldenberg DM; Vahdat LT
    J Clin Oncol; 2017 Jul; 35(19):2141-2148. PubMed ID: 28291390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.
    Loriot Y; Petrylak DP; Rezazadeh Kalebasty A; Fléchon A; Jain RK; Gupta S; Bupathi M; Beuzeboc P; Palmbos P; Balar AV; Kyriakopoulos CE; Pouessel D; Sternberg CN; Tonelli J; Sierecki M; Zhou H; Grivas P; Barthélémy P; Tagawa ST
    Ann Oncol; 2024 Apr; 35(4):392-401. PubMed ID: 38244927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.
    Kalinsky K; Diamond JR; Vahdat LT; Tolaney SM; Juric D; O'Shaughnessy J; Moroose RL; Mayer IA; Abramson VG; Goldenberg DM; Sharkey RM; Maliakal P; Hong Q; Goswami T; Wegener WA; Bardia A
    Ann Oncol; 2020 Dec; 31(12):1709-1718. PubMed ID: 32946924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes.
    Rizzo A; Rinaldi L; Massafra R; Cusmai A; Guven DC; Forgia D; Latorre A; Giotta F
    Future Oncol; 2024; 20(20):1427-1434. PubMed ID: 38864297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer.
    Fleming PJ; Karpio S; Lombardo N
    J Adv Pract Oncol; 2021 Sep; 12(7):747-752. PubMed ID: 34671504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.
    Tagawa ST; Balar AV; Petrylak DP; Kalebasty AR; Loriot Y; Fléchon A; Jain RK; Agarwal N; Bupathi M; Barthelemy P; Beuzeboc P; Palmbos P; Kyriakopoulos CE; Pouessel D; Sternberg CN; Hong Q; Goswami T; Itri LM; Grivas P
    J Clin Oncol; 2021 Aug; 39(22):2474-2485. PubMed ID: 33929895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma.
    Mathew Thomas V; Tripathi N; Agarwal N; Swami U
    Expert Rev Anticancer Ther; 2022 Apr; 22(4):335-341. PubMed ID: 35249433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases.
    De Moura A; Loirat D; Vaillant S; Korbi S; Kiavue N; Bello Roufai D; Escalup L; Desmaris R; Vaflard P; Cottu P; Pierga JY; Bidard FC; Cabel L; Acramel A
    Breast Cancer; 2024 Jul; 31(4):572-580. PubMed ID: 38600429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sacituzumab Govitecan-hziy in Breast Cancer.
    Kwapisz D
    Am J Clin Oncol; 2022 Jul; 45(7):279-285. PubMed ID: 35728046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
    Adams E; Wildiers H; Neven P; Punie K
    ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis.
    Caputo R; Buono G; Piezzo M; Martinelli C; Cianniello D; Rizzo A; Pantano F; Staropoli N; Cangiano R; Turano S; Paris I; Nuzzo F; Fabi A; De Laurentiis M
    Front Oncol; 2024; 14():1362641. PubMed ID: 38595817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer.
    Xie J; Li S; Li Y; Li J
    BMC Health Serv Res; 2023 Jun; 23(1):706. PubMed ID: 37386633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.